A single-arm, single-center, prospective Phase 2 study of pulsed high-dose fractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and tislelizumab in treating patients with driver gene-negative Stage IV NSCLC
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Nov 2024 New trial record